Olema's OP-3136 Phase 1 Data 'Encouraging' with Tumor Shrinkage, Partial Responses
OLMA has more than doubled off its 52-week low of $3.89.
Summary
Olema Oncology announced encouraging initial Phase 1 clinical data for its KAT6 inhibitor, OP-3136, in advanced solid tumors. The study showed acceptable tolerability, tumor shrinkage in over two-thirds of evaluable patients, and three partial responses (two confirmed). This positive clinical update follows the company's Q1 2026 report and 10-Q filing on May 12th, which included a wider net loss and a 'going concern' warning. Positive early-stage clinical data is critical for a clinical-stage biopharmaceutical company, potentially boosting its pipeline and attracting investor interest. The full data will be presented at the ASCO Annual Meeting on May 30, 2026.
At the time of this announcement, OLMA was trading at $14.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $3.89 to $36.26. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.